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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that causes
dementia. While molecular basis of AD is not fully understood, genetic factors are
expected to participate in the development and progression of the disease. Our
goal was to uncover novel genetic underpinnings of Alzheimer’s disease with a
bioinformatics approach that accounts for tissue specificity.
Findings: We performed genome-wide association studies (GWAS) for hippocampal
volume in two Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohorts. We used
these GWAS in a subsequent tissue-specific network-wide association study (NetWAS),
which applied nominally significant associations in the initial GWAS to identify disease
relevant patterns in a functional network for the hippocampus. We compared
prioritized gene lists from NetWAS and GWAS with literature curated AD-associated
genes from the Online Mendelian Inheritance in Man (OMIM) database. In the ADNI-1
GWAS, where we also observed an enrichment of low p-values, NetWAS prioritized
disease-gene associations in accordance with OMIM annotations. This was not
observed in the ADNI-2 dataset. We provide source code to replicate these analyses as
well as complete results under permissive licenses.
Conclusions: We performed the first analysis of hippocampal volume using NetWAS,
which uses machine learning algorithms applied to tissue-specific functional interaction
network to prioritize GWAS results. Our findings support the idea that tissue-specific
networks may provide helpful context for understanding the etiology of common
human diseases and reveal challenges that network-based approaches encounter
in some datasets. Our source code and intermediate results files can facilitate
the development of methods to address these challenges.
Findings
Alzheimer’s disease (AD) is a neurodegenerative disease that affects memory and be-
havior. Around 70 % of the risk is expected to be attributable to genetics [1]. Including
the well documented association with the gene APOE, previous studies have identified
22 susceptibility loci for late-onset Alzheimer’s disease (LOAD), of which 11 were
recently reported by a large meta-analysis [2]. Most existing genetic analyses lack the
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affected tissue context, which is crucial to the precise actions of genes, though some
eQTL analyses have begun to address this problem. For example, analysis of
eQTLs in brain samples from control individuals and those with LOAD identified
variants associated with changes in gene expression in the brain [3].
To identify genes that play a tissue-specific role in disease, we used the recently
developed network-wide association study (NetWAS) method, which takes the tissue-
specific functional roles of genes into account, to identify genes associated with differ-
ences in hippocampal volume [4]. We applied the NetWAS approach to genome-wide
association study (GWAS) results from ADNI using hippocampal volume as an endo-
phenotype. NetWAS identifies features in the hippocampus tissue-specific network that
are associated with nominally significant GWAS p-values, and it uses these features to
identify potentially novel AD gene associations. We evaluated the extent to which the
NetWAS approach using a hippocampus network could identify AD-associated genes
and compared results to the GWAS alone.
Data
Data used in this study were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 by the
National Institute on Aging (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical
companies and non-profit organizations, as a $60 million, 5-year public-private partnership.
The primary goal of ADNI has been to test whether serial magnetic resonance imaging
(MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cogni-
tive impairment (MCI) and early AD. Determination of sensitive and specific markers of
very early AD progression is critical to aid researchers and clinicians to develop new treat-
ments and monitor their effectiveness, and to reduce the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical
Center and University of California - San Francisco. ADNI is the result of efforts of
many co-investigators from a broad range of academic institutions and private corpora-
tions, and subjects have been recruited from over 50 sites across the U.S. and Canada.
The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by
ADNI-GO and ADNI-2. To date these three protocols have recruited over 1,500 adults,
ages 55 to 90, to participate in the research, consisting of cognitively normal older indi-
viduals, people with early or late MCI (EMCI or LMCI), and people with early AD. The
follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and
ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to
be followed in ADNI-2. Thousands of longitudinal imaging scans [5, 6], performance
on neuropsychological and clinical assessments [7] and biological samples [8] were
collected at baseline and at follow-up visits for all or a subset of participants.
Genome-wide genotyping data [9] are available on the full ADNI sample. For up-
to-date information, see www.adni-info.org.
Genotype data of all participants from both ADNI-1 and ADNI-2 were downloaded,
quality controlled, imputed to the Illumina 610Quad platform and combined, following
the procedure described in [10]. Freesurfer version 5.1 was used to extract hippocampal
volume and intracranial volume (ICV) measures from the 1.5 T baseline MRI scans of
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the ADNI-1 participants, and from the 3 T baseline MRI scans of the ADNI-2 partici-
pants, as previously described in [11]. Siblings and participants without hippocam-
pal volume were excluded. As a result, we included 748 subjects and 817 subjects
in the ADNI-1 and ADNI-2 analyses, respectively. GWAS analyses were performed
by PLINK v1.07 using a linear regression model covaried for age, gender, education
and ICV.
The analytic workflow
Our analytical workflow was designed to identify genes associated with differences in
hippocampal volume. Figure 1 provides an overview of our analytical strategy. To en-
sure reproducibility, we have used methods that are available from webservers and
open source software packages to ensure accessibility of this analysis for other re-
searchers. Because we performed a large number of NetWAS to evaluate the robustness
of results, the actual analyses were performed on a computing cluster. We provide our
source code and intermediate results under permissive licenses. The goal of phase I
was to calculate gene-based association p-values based on SNP association p-values
from the hippocampal volume GWAS. The goals of phase II were to reprioritize gene-
based associations using hippocampus functional network and to assess the concord-
ance of identified disease-gene associations with documented associations.
Phase I: gene-level analysis
We applied the versatile gene-based association study (VEGAS) webserver to calculate
gene-based p-values from individual SNP p-values, described in the data section above,
for associations with hippocampal volume endpoint [12]. VEGAS assigns SNPs to indi-
vidual genes using a window of 50 kb upstream and downstream from the gene se-







































Fig. 1 An overview of our analysis. In phase I, we mapped SNPs from the GWAS studies to genes and
calculated gene-based p-values from SNP p-values. In phase II, we focused on using hippocampus network
to reprioritize these genes. The efficacy of this approach was assessed with documented associations with
AD. NetWAS results from different cohorts were integrated using an average-score approach and assessed
for concordance with documented AD associations
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(LD). The ADNI data we used were restricted to non-Hispanic Caucasian participants
[10], so we used the HapMap CEU population for LD. This stage of analysis provided
us with gene candidates associated with the hippocampal volume endpoint from
the GWAS.
Phase II: tissue-specific functional network analysis
The gene-based p-values calculated in phase I were used as input for a NetWAS
analysis. NetWAS reprioritizes disease-gene associations using a functional network by
constructing a support vector machine classifier using nominally significant genes
(p < 0.01) as positive examples and non-associated genes as negative examples. The
resulting classifier, which learned patterns in the biological network associated with
nominal significance, was then applied back to the network to re-rank genes [4].
We performed NetWAS on the DISCOVERY supercomputer at Dartmouth. To
evaluate the stability of predictions and estimate the variance of multiple NetWAS
runs, we performed 1000 iterations of each analysis with randomly selected cross-
validation intervals. To evaluate potential underlying bias in the method towards
OMIM annotations, we also performed NetWAS on 1000 different GWAS for each co-
hort in which the associated genes had been permuted. Source code and intermediate
and final results for these analyses are provided under permissive open source licenses
[13] (code: BSD 3-clause; data: CC0).
The ultimate goal of this analysis was to use information about the tissue-specific
functions and relationships of genes to identify disease-associated genes more effectively
than GWAS. We mapped OMIM [14] annotations onto the Disease Ontology (DO) [15].
To assess the performance of this approach for this phenotype, we used the area under the
receiver-operator characteristic curve (AUC) to compare NetWAS, permuted NetWAS
and GWAS gene rankings. AUCs were calculated using annotations that were mapped to
the DO term for Alzheimer’s disease (DOID:10652) as gold standard positives.
Results and discussion
Using VEGAS, in phase I of the analysis we converted SNP-level association statistics
from two different ADNI studies into two sets of gene-level association statistics for
the hippocampal volume phenotype. These statistical associations were reprioritized in
phase II using NetWAS analyses that leveraged a functional network for the hippocam-
pus performed across 1000 independent sets of five-fold cross validation. To generate
an aggregate list, we summed the ranks for each NetWAS. Tabular complete results for
each of these analyses are available in the source code repository associated with this
paper (ADNI-1 VEGAS: data/vegas_adni1.xls; ADNI-2 VEGAS: data/vegas_adni2.xls;
NetWAS ADNI-1 and ADNI-2: combined-results.csv).
The underlying idea of NetWAS is that multiple truly associated genes may exhibit
nominal, though not genome-wide, significance, which a machine learning method
could use to extract phenotype-associated network features. Because NetWAS was
developed to identify network commonalities among nominally associated genes, we
generated quantile-quantile plots of observed VEGAS gene-wise p-values against a
uniform distribution. ADNI-1 showed slight inflation, suggesting that this GWAS
might represent a good NetWAS candidate (Additional file 1: Figure S1). ADNI-2 did
not show evidence of inflation (Additional file 2: Figure S2).
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We compared the GWAS ranked and NetWAS reprioritized genes to genes with a
documented association with Alzheimer’s disease in the OMIM database using the
AUC (Fig. 2). Comparing the GWAS against the 95 % confidence intervals, we found
that the NetWAS ranking more closely matched genes with a documented relationship
to AD than genes identified by the initial VEGAS analysis in the ADNI-1 cohort. In the
ADNI-2 cohort, this relationship was reversed but less pronounced. In both cases, the
scores for the NetWAS performed using the GWAS associations were outside of and
above the 95 % bootstrap confidence intervals for the mean of NetWAS with permuted
gene-significance.
We noted that in the NetWAS results generated from ADNI-1 GWAS, the top 14
genes all belonged to the protocadherin alpha gene cluster (PCDHA). This unusual re-
sult had not previously been observed in a NetWAS analysis, so we investigated both
network-based and association-based explanations. Examination of p-values from
VEGAS revealed multiple significant PCDHA genes (PCDHA1-13, PCDHAC1, PCDHAC2).
These associations could be driven by the same variants within the overall 50 kb window,
Fig. 2 Network reprioritization of AD GWAS identifies AD-associated genes. GWAS ranked and NetWAS
reprioritized genes are assessed for correspondence to genes known to be associated with Alzheimer’s
disease. We compared ADNI-1 and ADNI-2 to DO-annotated AD genes using AUC. The AUC for NetWAS in
ADNI-1 was significantly higher than that observed for the GWAS or the permuted NetWAS. The AUC
for NetWAS in ADNI-2 was significantly higher than the permuted NetWAS. Error bars indicate 95 %
confidence intervals via bootstrap
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as the PCDHA gene cluster includes multiple overlapping genes (Fig. 3). In the case that
these genes are from the same family, as with PCDHA genes, they may also have similar
network connectivity patterns, making it difficult for NetWAS to distinguish whether one
or all members of the gene family should be most closely associated with the disease. The
multiple associated genes by VEGAS also make it difficult for NetWAS to successfully dis-
tinguish involved members. These properties can, in certain circumstances, make it difficult
to pinpoint the principally associated gene. This multiple-mapping problem has previously
been reported to have impact on gene-set based analysis [16]. Our analysis demonstrates
that users should also be cognizant of this for network-based approaches. Gene-based asso-
ciation tests that attempt to control for SNPs with potential associations with multiple
genes may be required to address this challenge.
While a 50 kb window can lead to multi-gene mapping, it can also fail to capture
long-range interactions between SNPs and genes. For example, SNPs 500 kb from the
gene c-MYC were found to directly interact with the promoter of c-MYC, upregulating
the expression of this gene [17]. Such relationships cannot be captured by existing
gene-based association tests without creating additional multiple-mapping challenges.
Fig. 3 Significant SNP-wise p-values overlap with the entire PCDHA cluster. The Manhattan plot on the top
shows p-values of the SNPs in the PCDHA region. The genome view at the bottom indicates where the genes
are located in the genome. The overlap between significant SNPs and all PCDHA genes (PCDHA1-13) potentially
explains the significant associations for all genes in this family so that they are largely identified by NetWAS
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Gene-based association tests that account for potential long-range interactions through
both haplotype structures and 3D chromosomal organization information would help
to ameliorate this problem.
In summary, we have performed the first NetWAS for hippocampal volume, or any
AD-related phenotype, in AD patients and controls using the ADNI-1 and ADNI-2
cohorts. In the course of this analysis, we identified the need for new gene-based asso-
ciation tests that aim to solve multiple-mapping challenges for SNP-gene relationships.
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